

- mortality ratios in, in males
64:130, 132
- mortality ratios in, in smokers
64:149
- mortality ratios in, Japanese male smokers vs. nonsmokers
73:76, 77
- mortality ratios, pipe smokers vs. nonsmokers
67:35
- mortality trends in
64:137
- in nonwhites
64:209
- recurrent, incidence in smokers vs. ex-smokers
73:71, 74-77
- relationship of tobacco use and development of
71:354-357
- relative risk for cigar, pipe, and cigarette smokers
72:67; 73:76, 77, 197-199
- relative risk ratios from tobacco use
71:277, 358
- retrospective studies of
64:205-209
- risk ratios in
64:209
- in Seventh Day Adventists
64:209
- smokers vs. nonsmokers
69:58-59
- smoking in etiology of
64:32, 188, 189; 72:4, 67, 68
- summary of previous findings on relationship to smoking
68:89, 90; 74:57
- summary of retrospective studies
73:198, 199
- susceptibility to
64:189
- in Sweden, retrospective study of
64:205, 207
- vitamin deficiency in
64:212
- in women
64:234
- Laryngitis
reversibility of
64:275
- Larynx
atypical nuclei in cells of smokers
69:58-59
- effect of cessation of smoking on
69:59
- epithelial changes in, classification of
71:281, 283
- epithelial changes in, smoke induced
64:275
- hamster, C-14 labeled particulate deposition in
71:281-282
- histological changes in cigar, pipe, cigarette smokers vs. nonsmokers
73:197
- premalignant changes in, and smoking
69:5, 55
- see also* Vocal cords
- Laws
PL 89-92, requirements for smoking hazards literature review
71:7
- PL 91-222, requirements for smoking hazards literature review
71:7
- Lead arsenate
64:61
- Leaf constituents
hydroxy-coumarin as
64:145
- Leather workers
bladder neoplasm prevalence in
64:222, 224
- Leukemia
and cigarette smoke
67:148
- and tobacco tars
67:148
- Leukocytes
effects of cigarette smoke on, in guinea pigs
75:77, 78
- Leukoplakia
64:233
- experimentally induced, in rabbits
64:203
- oral neoplasm development in smokers and
72:68, 69
- as precancerous lesion,
64:142
- prevalence in tobacco chewing coal miners
73:75
- reverse smoking and,
73:76
- smoking and betel nut chewing
69:58
- smoking in etiology of
72:68, 69
- see also* Stomatitis nicotina
- Licorice
64:62
- Life expectancy
U.S.males, by cigarette consumption
68:9, 10
- Lip neoplasms
chewing tobacco in
64:202
- cigarette smoking in etiology of
73:190, 191
- cigar smoking in etiology of
73:190, 191
- mortality rates in United States
67:145
- pipe smoking in etiology of
64:32, 37, 188, 197, 204; 67:35, 145; 71:289; 72:4; 73:190, 191
- relative risk in pipe, cigar, and cigarette smokers vs. nonsmokers
73:190, 191
- retrospective studies of, by type of smoking
64:201
- snuff in
64:202

- summary of retrospective studies
 - 73:192
 - tobacco use relation to
 - 64:233; 71:361, 362, 365, 367
 - see also* Mouth neoplasms; Oral neoplasms
- Lipoproteins
 - infiltration in arterial walls, carbon monoxide effects on
 - 71:63
 - in smokers vs. nonsmokers
 - 71:99-102
- Liquid paraffins
 - 64:51
- Liver
 - nicotine effects on
 - 64:342
- Liver cirrhosis
 - 64:103, 342
 - and alcohol consumption
 - 67:40
 - mortality rates, and smoking
 - 67:39, 184-185
 - mortality rates, by age
 - 67:184
 - mortality rates, by amount smoked
 - 67:184
 - mortality rates, by sex
 - 67:184
 - mortality ratios, by age
 - 67:184
 - mortality ratios, by daily amount smoked
 - 67:184
 - mortality ratios, by sex
 - 67:184
 - mortality ratios, by smoking classification for men
 - 67:184
 - rates among cigarette smokers
 - 71:5
 - and smoking
 - 67:39, 184-185
- Lobeline
 - as antitobacco agent
 - 64:70, 354
- Local anesthetics
 - 64:354
- London
 - mortality from smog
 - 64:295
- London Transport Executive
 - cough and smoking among male employees of
 - 64:281, 286
- Longevity
 - 64:99
 - constitutional differences in
 - 64:112
- Longshoremen
 - coronary death rates in
 - 64:323
 - pulmonary function in
 - 64:292
 - respiratory conditions in
 - 64:289
- Los Angeles County General Hospital Study
 - 64:173
- Luminescence
 - techniques of, use in determining aromatic hydrocarbons in urine
 - 71:297
- Lung diseases
 - infections, and smoking, role in lung neoplasm development
 - 74:47, 48
 - in rabbits, similar to emphysema
 - 69:41
 - in women
 - 64:289
 - see also* Bronchitis; Bronchitis, chronic; Emphysema; Respiratory symptoms; Respiratory tract diseases
- Lung function
 - see* Pulmonary function; Respiratory function tests
- Lung neoplasms
 - 64:143, 144, 167
 - air pollution in etiology of
 - 67:140; 68:98, 99; 71:11; 73:72
 - amount smoked in
 - 64:105, 155, 175
 - anaplastic
 - 64:159, 160
 - in animals
 - 68:93
 - asbestos exposure and smoking as risk factors
 - 74:41-43; 75:49
 - in asbestos workers, by smoking habit
 - 67:143
 - benzo(a)pyrene induction of
 - 64:147
 - and blood cholesterol levels in male smokers
 - 69:57
 - causality
 - 64:30, 31, 37
 - cigarette smoking in
 - 64:31, 149, 175-196, 231; 71:11
 - and cigar smoking
 - 67:34, 138-140
 - classification of, in smokers vs. non-smokers
 - 67:140-141
 - classification systems compared
 - 64:174
 - decrease in risk of for ex-smokers
 - 69:57; 75:43
 - detection of by sputum analysis of smokers
 - 69:58
 - development in dogs following cigarette smoke inhalation
 - 71:239
 - and development of chronic bronchitis
 - 75:49
 - early smoking factor in
 - 64:158
 - effect of air pollution and smoking
 - 75:44, 47
 - effect of cessation of smoking on
 - 67:15-17, 34, 139-140
 - effect of sex on development
 - 71:11
 - environmental and atmospheric factors
 - 71:252-255

- epidemiological methods
 - 64:175-189
- epidemiological studies
 - 69:55-58; 72:60-65; 73:68-72; 74:37, 38; 75:44
- epidermoid, in male smokers
 - 69:57
- epithelial change in
 - 64:168, 170, 172
- etiology of
 - 64:8; 72:59, 60
- excessive smoking in
 - 64:7
- experimental
 - 67:35, 144-145; 74:43-52
- experimental induction by cigarette smoke
 - 67:144
- experimental induction by radioactive substances
 - 67:128
- experimental induction by tobacco smoke constituents
 - 67:145
- ex-smoker risk in
 - 64:158
- filtering of tobacco
 - 68:97
- foreign-born mortality rate in
 - 64:134
- genetic factors and
 - 64:167, 190, 191, 192, 193
- genetic factors and smoking as risk factors
 - 74:37
- group characteristics of tobacco use in smokers and nonsmokers
 - 71:240, 244, 329-333
- groupings
 - 71:246-334
- in heavy smokers
 - 64:151, 196, 230, 232
- histology of
 - 64:159, 160, 167-173; 67:140-144
- histology of, and smoking
 - 71:246-249; 74:38, 39, 44-46
- in human beings and laboratory animals
 - 67:145
- immunologic response to benzo(a)pyrene-induced tumor, in animals
 - 74:48, 49
- incidence by smoking classification
 - 67:34
- incidence in British males by amount smoked
 - 72:62
- incidence in cigar and/or pipe smokers vs. nonsmokers
 - 74:39, 40
- incidence in cigar smokers
 - 68:95, 96
- incidence in Czechoslovakian males by amount smoked
 - 72:61
- incidence in Jewish vs. non-Jewish women
 - 72:63, 64
- incidence in male smokers
 - 69:4
- incidence in Norway
 - 69:55-56
- incidence in pipe smokers
 - 68:95
- incidence in smokers vs. nonsmokers in India
 - 74:37, 38
- incidence in smokers vs. nonsmokers in Jersey, Channel Isles
 - 73:70
- incidence in smokers vs. nonsmokers in LaPlata, Argentina
 - 73:70
- incidence in smokers vs. nonsmokers in Philadelphia
 - 73:70
- incidence in uranium miners
 - 72:64, 65
- incidence in women
 - 68:97; 69:4, 57
- incidence in women smokers vs. nonsmokers
 - 74:39, 40
- income class gradients in
 - 64:134
- increased mortality from
 - 64:25, 26, 128, 135, 136, 139, 140, 141, 185, 220, 231, 232
- increase in mortality of female smokers
 - 75:47
- inhalation patterns and
 - 73:203
- Kreyberg classification of
 - 64:35, 159, 173, 174
- Kreyberg study
 - 69:55-56
- in men, smoking as cause
 - 67:33, 131
- microscopic determination of
 - 64:140
- mortality from chromium compounds
 - 71:257-258
- mortality rates
 - 64:36, 105, 133, 134, 135, 138, 139, 140, 141, 176; 67:8, 34, 140; 68:68; 69:57
- mortality rates, age-specific
 - 64:36
- mortality rates, by age
 - 67:132-137; 68:94-99
- mortality rates, by amount smoked
 - 64:105, 175; 67:134-140
- mortality rates by cigarette consumption, by country
 - 64:176
- mortality rates, by degree of inhalation
 - 67:134-136
- mortality rates, by sex
 - 67:134, 140; 68:94-99
- mortality rates, by smoking characteristics
 - 67:131-140
- mortality rates, by smoking classification
 - 67:34, 138-140
- mortality rates, by smoking history
 - 67:134-137
- mortality rates, effect of cessation of smoking on
 - 67:4, 15, 34, 139

mortality rates expected in U.S. in 1970
 71:237, 239
 mortality rates, for men
 64:132, 175, 176; 67:132, 134-135,
 137, 139-140; 74:43
 mortality rates, for women
 64:132, 135, 175; 67:34-35,
 133-134, 136, 153
 mortality rates in asbestos workers,
 smokers vs. nonsmokers
 73:73
 mortality rates in Britain
 64:195
 mortality rates in British physicians vs.
 general population
 67:16-17; 73:70
 mortality rates in, errors in measurement
 of
 64:140
 mortality rates in, occupational differ-
 ences in
 64:95
 mortality rates in, sex differences in
 64:177, 178, 179
 mortality rates in smelter workers ex-
 posed to arsenic
 71:257
 mortality rates in smokers
 64:29, 162
 mortality rates in smokers and nonsmok-
 ers
 71:240-243
 mortality rates in smokers in Norway
 and Finland
 71:245-246
 mortality rates in Sweden
 64:176
 mortality rates in United States
 67:34; 71:239
 mortality rates, smoking and
 67:3, 10, 34
 mortality rates, smoking duration and
 64:36, 175; 71:240, 244
 mortality ratios
 64:103, 113, 148, 149, 162, 175
 mortality ratios, by amount smoked
 67:134-140
 mortality ratios, by degree of inhalation
 67:134-136
 mortality ratios, by sex
 67:134, 140
 mortality ratios, by smoking charac-
 teristics
 64:164; 67:134-136
 mortality ratios, by smoking classifica-
 tion
 67:138-140
 mortality ratios, by smoking history
 67:134-137
 mortality ratios for cigar, pipe, and
 cigarette smokers vs. nonsmokers
 73:203-205
 mortality ratios for women
 67:34-35, 136, 153
 mortality ratios in Japanese by amount
 smoked and age started smoking
 73:69
 mortality ratios in Japanese males by
 amount smoked
 72:61
 mortality ratios in Japanese women
 72:63
 mortality ratios in, variables affecting
 64:163
 mortality studies of, limitations of
 64:163
 multiple primary, autopsy findings
 67:141-142
 multiple primary, in smokers
 67:35
 mustard gas in
 64:195, 196
 nonrespondent rates, in surveys of
 64:151
 oat-cell, in male smokers
 69:57
 observed mortality in
 64:118
 occupational exposures
 64:193, 194; 71:12
 occupational exposures and smoking
 73:67
 particle deposition in bronchi and site of
 74:44, 45
 Philadelphia Pulmonary Neoplasm Re-
 search Project histopathologic study
 74:38
 pipe and cigar smoking in
 64:31, 37, 192, 196, 233
 pipe smoking
 67:34, 138-140
 and polonium
 67:128
 prevalence in females
 64:37
 prevalence in males
 64:35, 37
 prevalence in males and females by
 tumor type
 71:246, 250
 prevalence in smokers vs. nonsmokers in
 Czechoslovakia
 73:70
 prevalence of, age factors in
 64:177, 178, 179
 prevalence of, in smokers
 64:151
 prevalence ratios in
 64:182, 184, 185
 previous respiratory history in
 64:195, 196
 prospective study in Czechoslovakian
 males
 72:61
 prospective study in Japanese adults
 72:4, 60, 61; 73:68, 69
 race as a factor, smokers vs. nonsmokers
 73:70
 radioactive induction of
 64:172
 reduction in number using filter-type
 cigarettes
 71:275
 relationship of asbestos and smoking to
 71:257

- relationship of chronic bronchitis and smoking to
 - 72:62
- relative risk in cigar, pipe, and cigarette smokers vs. nonsmokers
 - 73:203, 206-208
- relative risk in ex-smokers by length of cessation and previous duration of habit
 - 72:62-64
- relative risk in ex-smokers vs. continuing smokers
 - 73:72
- relative risk in pipe/cigar smokers
 - 73:67, 68
- retrospective studies of
 - 64:150-165, 230, 231
- retrospective study methods for smoking relationships
 - 71:240, 323-328
- risk ratios in
 - 64:160, 183, 184, 185, 187, 188
- risk reduction with filter vs. nonfilter cigarettes
 - 74:40, 41
- role of aryl hydrocarbon hydroxylase activity and polyaromatic hydrocarbons in
 - 74:49-52
- role of pulmonary infections and smoking in etiology of
 - 74:47, 48
- and selenium in cigarettes
 - 67:128
- in Seventh Day Adventists
 - 64:322
- sex ratios in
 - 64:133
- sex ratio statistic
 - 74:40
- smoke inhalation in, urban-rural differences in
 - 64:133, 186, 194, 195
- and smokers
 - 69:4-5
- of smokers, in Rhodesia
 - 69:57
- smoking in etiology of
 - 67:32-34, 141-144; 71:3, 237, 276; 72:4, 5, 59, 60; 73:67
- and smoking in men
 - 67:34
- and smoking in women
 - 67:10, 34; 71:246, 251
- summary of previous findings
 - 75:3, 5-8
- summary of previous findings on relationship to smoking
 - 68:89, 90; 74:35-37
- summary of recent findings
 - 75:43
- summary of retrospective studies
 - 73:206-208
- types implicated in smoking
 - 71:237
- typing of
 - 64:35, 159, 173, 174, 175

- and ulcers, relation to smoking
 - 69:57
- in uranium miners by smoking habit
 - 67:143
- World Health Organization classification of
 - 64:173, 174
- Xenon-133 washout technique for detection of
 - 74:43, 44
- see also* Respiratory tract neoplasms; and specific histological types

Lungs

- alveolar tissue, effect of smoking on
 - 64:274, 275; 67:30
- arterioles, effect of pipe/cigar smoking vs. cigarette smoking on
 - 73:217
- bactericidal activity, effect of nitrogen dioxide on, in mice
 - 74:103
- compliance
 - 64:292
- effect of cigarette smoke in laboratory animals
 - 67:106
- effect of cigarette smoke on tissue
 - 64:274; 71:343-345
- effect of nitrogen dioxide
 - 64:266; 69:41
- hamster, C-14 labeled particulates deposition in
 - 71:281-282
- histology of pipe/cigar smokers vs. cigarette smokers
 - 73:217
- histopathological differences in smokers vs. nonsmokers
 - 73:48, 49
- hygiene
 - 64:267, 268
- injury
 - 64:270
- lesions
 - 64:73, 295
- parenchyma
 - 64:27, 35, 167, 263, 264, 272, 301
- parenchyma, effect of smoking on
 - 67:144
- pathological changes in emphysema patients by smoking history and sex
 - 67:105
- pathological effects of smoking on
 - 64:165-172; 69:5
- physiology, new animal model for testing of
 - 74:102
- polonium-210 levels, smokers vs. nonsmokers
 - 67:128
- scars and susceptibility to carcinogens
 - 69:64
- see also* Respiratory system

Lymphosarcoma

- and cigarette smoke
 - 67:148
- and tobacco tars
 - 67:148

- Lysozyme
 - secretion by rabbit pulmonary alveolar macrophages 69:42
- Macrophages, alveolar
 - decrease in pinocytosis, in smokers vs. nonsmokers 75:76
 - effect of cigarette smoke on 67:110; 69:42; 71:165; 73:52, 53; 74:50
 - effect of nitrogen dioxide 73:54
 - effect of tobacco smoke 72:47, 48
 - lysozyme secretion in rabbits 69:42
 - and pathogenesis of chronic bronchopulmonary disease 64:43
 - reduction of enzymes in smokers 69:42-43
 - response to migration inhibition factor or antigens, in smokers vs. nonsmokers 75:76, 77
 - in sputum specimens of smokers vs. nonsmokers 72:48
- Macrophages, peritoneal
 - effect of nicotine on, in mice 74:105
- Macrophages, pulmonary
 - effect of cigarette smoke extract, in sheep lungs 74:105
 - effect of cigarette smoke, in guinea pigs 75:77, 78
 - effect of cigarette smoke, in rabbits 74:104, 105
 - effect of smoking 72:3, 4, 47-48; 73:55
 - morphologic differences in smokers vs. nonsmokers 72:4, 47-48
 - summary of recent findings 75:78
- Mainstream smoke
 - see* Smoke streams
- Malathion 64:62, 145
- Malaya
 - betel nut-tobacco chewing in 64:203
- Mammals
 - effect of cigarette smoke tars on cells 71:343
 - nicotine metabolism in 64:71, 72, 73, 74
- Marihuana 64:349
- Marital status
 - bladder neoplasms and 64:224
 - smoking prevalence by 64:364
- Masculinity
 - 64:383, 384, 385
 - smoking behavior association with 64:372, 373
- Massachusetts General Hospital 64:141, 174
- Mass spectrometry 64:51
- Maternal-fetal exchange
 - effect of nicotine 72:88
 - polycyclic hydrocarbons and 73:119
 - see also* Smoking, maternal
- Maternal smoking
 - see* Smoking, maternal
- Maximum breathing capacity 64:290
- Mayo Clinic 64:322
- Mean expiratory flow rate 64:290
- Measurement errors
 - in smoking studies 64:97, 111
- Men
 - arteriosclerosis obliterans in 64:326
 - bladder neoplasms in 64:219, 222, 224, 255
 - breathlessness in 64:286, 287
 - bronchitis prevalence in 64:289
 - chest illness in 64:288
 - chronic cough in 64:281, 282, 285
 - college students, smoking patterns in 64:369
 - coronary diseases in 64:321, 322, 327
 - cough and sputum prevalence in 64:284
 - epithelial change in 64:170, 173
 - forced expiratory volume in 64:290, 291
 - increased lung neoplasm prevalence in 64:192
 - irreversible obstructive lung disease in 64:288, 289
 - laryngeal neoplasms 64:212
 - lung neoplasms in 64:183, 186
 - lung neoplasms in, by amount smoked 64:155
 - lung neoplasms in, cigarette smoking in relation to 64:31, 37
 - lung neoplasms in, early smoking in 64:158
 - lung neoplasms in, prevalence of 64:231
 - lung neoplasms in, prevalence of, in Seventh Day Adventists 64:363

- mortality rates in
 - 64:28, 85
- mortality ratios in
 - 64:28
- mortality trends in
 - 64:133, 135, 192
- neoplasm mortality in, by site
 - 64:132
- neoplasm mortality rates in
 - 64:135, 137, 175, 176
- neoplasm mortality ratios in
 - 64:130, 132, 175
- nonsmokers, U.S. incidence of, by age
 - 64:178
- oral neoplasms
 - 64:202, 204
- risk ratios in
 - 64:161
- risk ratios in, in bladder neoplasms
 - 64:222
- single, mortality trends in
 - 64:101
- smokers, U.S. incidence of, by age
 - 64:178
- smoking and respiratory symptoms in
 - 64:286
- smoking habits of
 - 64:231
- smoking patterns in
 - 64:177, 178, 179
- smoking prevalence in
 - 64:363
- sputum production in
 - 64:283
- Menopause
 - and cardiovascular disease, in women smokers vs. nonsmokers
 - 74:10, 19
 - coronary death rates following
 - 64:321
- 1,8-*p*-Menthadiene
 - 64:51
- Menthol
 - 64:62
- Mesenchymal tumors
 - classification of
 - 64:174
- Mesotheliomas
 - classification of
 - 64:174
- Metal mine workers
 - pulmonary function in
 - 64:299
- Metals
 - as carcinogens
 - 64:166, 167, 189, 193, 194, 230, 232
- Metal-working trades
 - neoplasm risks in
 - 64:134
- Metaplasia
 - 64:170
 - anaplasia, lung neoplasms and
 - 64:172
 - as precancerous change
 - 64:166
 - squamous, experimentally induced in lungs by cigarette smoke
 - 67:144
 - squamous, in stomatitis nicotina
 - 64:271
- squamous, nickel carbonyl in
 - 64:166
- Methacrolein
 - as suspected contributor to health hazards of smoking
 - 72:145
- Methane
 - in tobacco smoke
 - 64:60
- Methanol
 - 64:60
- Methoxy-coumarin
 - 64:145
- Methyl alcohol
 - as suspected contributor to health hazards of smoking
 - 72:145
- 6-Methylanthranthrene
 - carcinogenicity, as component of cigarette smoke
 - 72:66
- Methyl chloride
 - 64:60
- 3-Methylcholanthrene
 - 64:166
 - effects during pregnancy in laboratory animals
 - 73:117
- 20-Methylcholanthrene
 - 64:203-228
- Methyl ethyl ketone
 - 64:52, 60
- Methylglycerol
 - 64:62
- N-methylnicotinamide
 - urinary excretion, effect of smoking
 - 67:156, 71:297
- Methyl nitrite
 - 64:60
- Methyl protoanemonin
 - carcinogenicity of
 - 64:145
- Metrazol
 - treatment of depression with
 - 64:352
- Metropolitan Life Insurance Company
 - 64:344
- Mice
 - bladder neoplasms in, induction by tryptophan metabolites
 - 71:296
 - embryo, lethal effects of nicotine on
 - 71:411
 - esophageal epithelium of, alcoholic benzo(a)pyrene penetrability of
 - 71:292
 - esophageal epithelium of, oil-dissolved benzo(a)pyrene penetrability of
 - 71:292
 - genetic variation in
 - 64:167
 - induction of bladder neoplasms in
 - 64:219, 223
 - induction of bronchitis in
 - 64:272
 - induction of epidermoid neoplasms in
 - 64:166

- induction of hepatomas in
 - 64:145
- induction of oral neoplasms in
 - 64:202
- induction of neoplasms in
 - 64:143, 144, 146
- induction of pulmonary adenomas in
 - 64:143, 144
- induction of skin neoplasms in
 - 64:143
- induction of squamous cell carcinoma in
 - 64:228
- inhibition of phagocytic clearance in
 - 64:269
- irritation in, by formaldehyde
 - 64:260
- lung neoplasm incidence in, from chromium oxide dust exposure
 - 71:258
- lungs of, effects of cigarette smoke on
 - 64:165; 71:159, 343, 344
- pulmonary carcinoma induction in, following asbestos dust inhalation
 - 71:257
- pulmonary changes from chronic nitrogen oxide inhalation
 - 71:161, 220
- pulmonary clearance in, cigarette smoke effects on
 - 71:170
- resistance to pneumonia bacteria following cigarette inhalation
 - 71:173
- respiratory tract of, cigarette smoke inhalation effect on
 - 71:268-269, 349-353
- skin painting of, smoke condensates effects on
 - 71:267, 337-342
- spontaneous neoplasms in
 - 64:165
- spontaneous pulmonary adenomas in
 - 64:165
- Migrants
 - lung neoplasm rates in
 - 64:194
- Migration
 - lung neoplasm risks in
 - 64:195
- Migration inhibition factor
 - effects on alveolar macrophages, in smokers vs. nonsmokers
 - 75:76, 77
- Mill workers
 - breathlessness in
 - 64:286
 - chronic cough in
 - 64:280
 - chronic respiratory disease in
 - 64:289, 299
- Mineral oil
 - carcinogenicity of
 - 64:147, 148, 229
- Miners
 - forced expiratory flow rates in
 - 64:290
 - forced expiratory volume in
 - 64:293, 294
 - impairment of pulmonary function in
 - 64:299
 - mucous gland hyperplasia in
 - 64:271
 - respiratory symptoms in
 - 64:298, 299
- Minnesota Multiphasic Personality Inventory
 - 64:366
- Mitochondria
 - effect of tobacco smoke on, in rat liver
 - 74:104
- Molders
 - neoplasm risk in
 - 64:134
- Mollusks
 - ciliary function in, effect of cigarette smoke on
 - 71:223
- Monkeys
 - atherogenic effects of carbon monoxide and hypoxia
 - 71:64
 - ciliary function in, effect of cigarette smoke on
 - 71:222
 - fetal bronchial tubes of, effects of cigarette smoke on
 - 71:345
 - rhesus, development of bladder neoplasms from 2-naphthylamine
 - 71:296
 - squirrel, nitrogen oxide effects on resistance to pneumococcus
 - 71:173
- Monoamine oxidase inhibitors
 - effect on rabbits receiving nicotine
 - 69:27
- Monohydric alcohols
 - 64:52
- Morbidity
 - bladder neoplasms, and smoking
 - 67:155
 - bronchitis, and smoking
 - 67:3, 30, 96-99
 - bronchitis, in smoking discordant twin pairs
 - 67:102-103
 - chronic bronchopulmonary diseases
 - 72:39-41; 73:36-39
 - coronary diseases, smokers vs. nonsmokers
 - 67:53-54
 - emphysema, and cigar smoking
 - 67:97
 - emphysema, and pipe smoking
 - 67:97
 - emphysema, and smoking
 - 67:3, 30, 96-99
 - lung neoplasms, and smoking
 - 67:3
 - peptic ulcers, and smoking
 - 67:40
 - respiratory diseases, smokers vs. nonsmokers among college students
 - 67:98
 - respiratory symptoms
 - 75:62, 63

- and smoking
 - 67:6, 19
- and smoking in college students
 - 67:98
- and smoking in 45-64 age group
 - 67:24
- studies of
 - 64:127, 133, 293, 294
- Morbidity rates
 - bronchitis, by age and smoking history
 - 67:96-98
 - bronchitis, by sex and smoking history
 - 67:96-98
 - coronary disease, smokers vs. nonsmokers by age
 - 67:54
 - emphysema, by age and smoking history
 - 67:96-98
 - emphysema, by sex and smoking history
 - 67:96-98
 - smokers vs. ex-smokers
 - 67:15
 - smokers vs. nonsmokers, by age
 - 67:19-24
 - smokers vs. nonsmokers, by amount smoked
 - 67:19-24
 - smokers vs. nonsmokers, by sex
 - 67:19-24
 - smokers vs. nonsmokers, by smoking history
 - 67:19-24
- Morbidity ratios
 - angina pectoris, by smoking habit in males
 - 68:20
 - angina pectoris, smokers vs. nonsmokers,
 - 67:59
 - coronary diseases
 - 69:19
 - coronary diseases, smokers vs. nonsmokers
 - 67:59; 71:21-22, 24, 30-35
 - coronary diseases, smokers vs. nonsmokers and lung function
 - 67:56
 - coronary diseases, smokers vs. nonsmokers by age
 - 67:54
 - coronary diseases, smokers vs. nonsmokers by blood cholesterol levels
 - 67:55
 - coronary diseases, smokers vs. nonsmokers by blood pressure values
 - 67:55
 - coronary diseases, smokers vs. nonsmokers by personality characteristics
 - 67:57
 - coronary diseases, smokers with predisposing factors
 - 71:24
 - coronary diseases, smoking and
 - 71:32-35, 37, 39
 - coronary diseases, smoking habit in males
 - 68:17, 18
 - coronary diseases, retrospective studies
 - 71:40, 93-97
- in Danish twins, smoking effects on
 - 71:49-51
- development of COPD in smokers vs. nonsmokers
 - 71:145, 195-205
- myocardial infarction, by risk factors in males
 - 68:23
- myocardial infarction, smokers vs. nonsmokers
 - 67:59
- myocardial infarction, smokers vs. nonsmokers by physical activity
 - 67:56
- Mortality rates
 - 64:25, 27, 30, 35, 36, 37, 84, 101, 162, 301
 - by age
 - 67:9-10, 12-13, 23
 - by age, and smoking history
 - 67:10; 68:6
 - by age, for men
 - 67:9, 10
 - by age, for women
 - 67:23
 - age started smoking and
 - 64:29, 111
 - alcoholism, relation to smoking
 - 67:10
 - amount smoked and
 - 64:111; 67:9, 23
 - aortic aneurysm, for men by amount smoked
 - 69:16
 - arteriosclerosis
 - 64:25, 321; 67:28
 - bladder neoplasms, by amount smoked
 - 67:155
 - bladder neoplasms, by sex
 - 67:154
 - bladder neoplasms, by smoking classification
 - 67:155
 - bladder neoplasms, effect of cessation of smoking on
 - 67:155
 - bladder neoplasms, for men by age
 - 67:154
 - bladder neoplasms, in United States
 - 67:154
 - from bladder neoplasms in U.S. for 1967
 - 71:293
 - bronchitis
 - 64:25, 297; 67:8, 90-91; 68:66-68
 - bronchitis, and smoking
 - 67:3, 90-96
 - bronchitis, effect of cessation of smoking on
 - 67:94, 96
 - from bronchopulmonary disease
 - 71:141-145
 - cardiovascular diseases
 - 69:17
 - cerebrovascular diseases, and athletic activity
 - 67:68
 - cerebrovascular diseases, and coronary disease history
 - 67:68

cerebrovascular diseases, and parental death history
 67:68
 cerebrovascular diseases, and smoking
 67:68
 cerebrovascular diseases, by age
 67:66; 75:31
 cerebrovascular diseases, by sex
 67:66; 75:31
 cerebrovascular diseases, smokers vs. nonsmokers
 71:66-67, 68-70
 cerebrovascular diseases, smoking classification
 67:66; 75:31
 in chronic bronchopulmonary disease
 64:301; 72:38, 39; 73:36-39
 in chronic bronchopulmonary disease, cigar/pipe smokers vs. cigarette smokers and nonsmokers
 73:216, 217
 cigar smokers vs. nonsmokers
 67:8
 in cigar smoking
 64:30; 67:7
 compared rates for cigarette vs. pipe/cigar ex-smokers
 73:172, 173
 Connecticut data on
 64:132
 coronary diseases
 64:25, 320, 321; 67:8, 25-28, 47; 71:21; 75:14
 coronary diseases, among physicians
 68:17
 coronary diseases, and age
 67:47, 50-51; 69:13-14; 74:6; 75:14
 coronary diseases, by amount smoked
 67:51; 69:12-13, 17
 coronary diseases, by blood cholesterol
 69:17
 coronary diseases, by blood pressure
 69:14, 17
 coronary diseases, by relative weight
 69:14
 coronary diseases, by sex
 67:47, 50; 69:13-14
 coronary diseases, by smoking habit
 67:51; 69:14
 coronary diseases, effect of cessation of smoking on
 67:25, 28, 47-49, 50
 coronary diseases in Japanese men and women by cigarette consumption and age started smoking
 73:7, 8
 coronary diseases in middle-aged men in seven countries
 74:6
 coronary diseases in survivors of myocardial infarction, smokers vs. nonsmokers
 74:4-6
 coronary diseases, male smokers vs. ex-smokers by age
 67:49
 coronary diseases, paired combinations of high risk characteristics in
 71:25
 coronary diseases, retrospective studies
 71:40 93-97
 coronary diseases, smokers vs. ex-smokers
 67:9; 69:15
 coronary diseases, smokers vs. ex-smokers by amount smoked
 67:49
 coronary diseases, smokers vs. ex-smokers by smoking history
 67:51
 coronary diseases, smokers vs. nonsmokers
 69:12-13, 15-17; 71:24, 26-29; 74:3-6
 coronary diseases, smoking and
 67:10, 27, 65-66
 in Danish twins, smoking effects on
 71:51
 differences in rates, defined
 68:7
 digestive tract neoplasms, by amount smoked
 67:147
 digestive tract neoplasms, by smoking classification
 67:147
 duration of smoking in
 64:29, 36
 early smoking and, excess in, in smokers
 64:29, 30, 35, 36, 84, 111, 162, 301
 emphysema
 64:25; 67:3-4, 8, 90-91; 68:66-68
 emphysema, effect of cessation of smoking on
 67:7, 24, 29
 esophageal neoplasms
 67:150, 153; 68:102; 71:289
 esophageal neoplasms, by age
 67:150
 esophageal neoplasms, by amount smoked
 67:150
 esophageal neoplasms, by smoking classification
 67:150
 esophageal neoplasms, for men by age
 67:150
 esophageal neoplasms, for women
 67:153
 esophageal neoplasms in Japanese males by smoking and drinking characteristics
 72:71
 in former smokers, relation to CHD
 71:46, 47-48
 in heavy smokers
 64:36, 107, 111, 163
 inhalation patterns and
 64:111; 68:5
 from kidney neoplasms in U.S. for 1967
 71:296
 in laryngeal neoplasms
 64:205; 67:153; 68:101, 102
 laryngeal neoplasms, by age
 67:148-149
 laryngeal neoplasms, by amount smoked
 67:149

laryngeal neoplasms, by sex
 67:148
 laryngeal neoplasms, by smoking classification
 67:149
 laryngeal neoplasms, for women
 67:148
 from laryngeal neoplasms, in Japanese smokers vs. nonsmokers
 68:102
 lip neoplasms, in United States
 67:145
 liver cirrhosis, and smoking
 67:40, 184
 liver cirrhosis, by age
 67:184
 liver cirrhosis, by amount smoked
 67:184
 liver cirrhosis, by sex
 67:184
 liver cirrhosis, for men
 67:184
 lung neoplasms
 64:25, 29; 67:8, 153; 68:68, 94-99; 69:57
 lung neoplasms, and smoking
 67:3
 lung neoplasms, by age
 67:34, 134-137, 140
 lung neoplasms, by amount smoked
 67:137, 140
 lung neoplasms, by birth cohorts
 67:131-133
 lung neoplasms, by sex
 67:134, 137, 140
 lung neoplasms, by smoking characteristics
 67:134-136, 140
 lung neoplasms, by smoking classification
 67:136, 140
 lung neoplasms, by smoking exposure
 67:34
 lung neoplasms, by smoking habit
 67:136, 140
 lung neoplasms, by smoking history
 67:134-137
 lung neoplasms, cigar smokers
 67:34, 140
 lung neoplasms, effect of cessation of smoking on
 67:34, 140
 lung neoplasms, effect of reduction of smoking on
 67:4
 from lung neoplasms expected in 1970
 71:237, 239
 lung neoplasms, ex-smokers
 67:140
 lung neoplasms, for men
 67:34, 131, 133-137, 139-140
 from lung neoplasms for 1939 vs. 1967 in U.S.
 71:239
 lung neoplasms, for women
 67:132-133, 136, 153; 75:47
 lung neoplasms in Japanese women
 72:63
 from lung neoplasms in smelter workers exposed to arsenic
 71:257
 lung neoplasms, pipe smokers
 67:140
 lung neoplasms, reduction in, British physicians
 67:15
 male-female ratios in
 64:133
 mouth neoplasms, by age and amount smoked
 67:146
 mouth neoplasms, by smoking classification
 67:146
 mouth neoplasms, for women
 67:153
 mouth neoplasms, in United States
 67:145-146
 from myocardial infarction
 75:14
 neoplasms
 64:128, 129, 130, 131, 132, 136, 137, 138, 139
 neoplasms, by site, in women
 64:132
 neoplasms, increase in
 64:127, 136
 neoplasms, in Japanese smokers vs. nonsmokers
 68:17
 in nonwhites
 64:218
 occupations
 64:134; 67:11
 from oral neoplasms in 1967
 71:285
 overall rates for cigar smokers vs. pipe smokers
 73:179, 180
 overall rates for pipe/cigar smokers and dose-response relationships
 73:180-189
 overall rates for pipe/cigar smokers vs. nonsmokers
 73:179, 180
 overall rates from cancer in pipe and cigar smokers
 73:189
 pancreatic neoplasms
 68:103; 72:74
 pancreatic neoplasms by age
 67:158-159
 pancreatic neoplasms, by amount smoked
 67:159
 pancreatic neoplasms, by sex
 67:153, 158, 159
 pancreatic neoplasms, by smoking classification
 67:159
 paralysis agitans
 67:8
 peptic ulcer
 67:40, 181-182; 71:423
 peptic ulcer, by age
 67:181
 peptic ulcer, for men
 67:181-182

peptic ulcer, smokers vs. ex-smokers
 67:181
 pharyngeal neoplasms
 67:153
 pharyngeal neoplasms, by smoking classification
 67:35
 pharyngeal neoplasms, for women
 67:153
 in pipe smokers
 64:30; 68:6
 pipe smokers vs. nonsmokers
 67:10
 Poisson distribution of
 64:117, 118
 reduction in, effect of cessation of smoking
 67:16
 from renal neoplasms in males, by age, type and smoking habit
 68:105, 106
 respiratory tract neoplasms, and smoking
 67:5-7, 9-10, 147
 rural vs. urban
 64:133; 67:11
 in selected diseases
 64:26
 by sex
 67:12-13
 of smokers, non- and ex-smokers
 68:5-8, 69
 smokers vs. ex-smokers
 67:9, 15
 smokers vs. ex-smokers, by smoking history
 67:9
 smokers vs. nonsmokers
 67:8-9, 19; 71:3
 and smoking
 67:5-9; 69:3
 by smoking history
 67:9-10, 23
 stomach neoplasms, by age
 67:157-158
 stomach neoplasms, by amount smoked
 67:157-158
 stomach neoplasms, by smoking classification
 67:157-158
 stomach neoplasms, effect of cessation of smoking
 67:157-158
 stroke
 69:17
 stroke, by age
 67:67; 69:12-13
 stroke, by amount smoked
 67:67; 69:12-13
 stroke, by sex
 69:12-13
 stroke, smokers vs. ex-smokers
 69:15
 stroke, smokers vs. nonsmokers
 69:12-13, 15
 in Swedish twins, smokers vs. nonsmokers
 71:51
 studies of
 64:100
 study of Chicago Peoples Gas Light and Coke Co. employees
 69:16-17
 summary of previous findings
 75:3-8, 13
 summary of previous findings on relationship to smoking
 68:5-10
 trends
 64:135, 140
 urinary tract neoplasms, by age
 67:154
 urinary tract neoplasms, by amount smoked
 67:154
 urinary tract neoplasms, by smoking classification
 67:154
 urogenital neoplasms, by age
 67:154
 U.S. male veterans from CHD
 71:26, 38
 in veterans
 64:88, 293
 in women
 64:133
 in women smokers
 67:7, 9; 68:6, 8, 9
 Mortality ratios
 64:36, 84, 99, 101, 118, 119; 69:12-13, 18
 after cessation of smoking
 64:29, 111
 age effects on
 64:36, 87
 alcohol consumption and
 64:112
 by amount smoked
 67:150, 153
 aortic aneurysm, for men by amount smoked
 69:16
 behavioral factors in
 64:101
 bladder neoplasms
 67:36, 154
 bronchitis
 64:28, 29, 293; 67:90, 94
 cerebrovascular diseases, by age
 67:66
 cerebrovascular diseases, by sex
 67:66
 cerebrovascular diseases, by smoking classification
 67:66
 in cigarette smokers
 64:28, 29, 35
 in coronary diseases
 64:29, 184
 coronary diseases, associated with other complicating diseases
 67:52
 coronary diseases, by age
 67:25-26, 49, 51-52; 69:12-13, 18
 coronary diseases, by amount smoked
 67:49
 coronary diseases, by blood pressure status
 67:52

- coronary diseases, by sex
67:49; 69:12-13
- coronary diseases, by smoking habit
67:51-52
- coronary diseases, by smoking history
67:25-26
- coronary diseases, by sociocultural mobility status
67:57
- coronary diseases, for men by age
67:48
- coronary diseases, for men by amount smoked
67:48
- coronary diseases, smokers vs. ex-smokers
69:15
- coronary diseases, smokers vs. nonsmokers
69:12-13, 15
- coronary diseases, with high risk characteristics, estimated
71:25
- daily cigarette consumption and
64:89
- definition of
64:28, 117; 67:11; 68:6
- duration of smoking in
64:111
- educational level factors in
64:112
- in emphysema
64:28, 29
- esophageal neoplasms, by age
67:150
- esophageal neoplasms, prospective and retrospective studies
71:289-291
- in ex-smokers
64:104
- genetic factors in
64:36, 112, 113
- in influenza, in smokers
64:276
- inhalation effects on
64:36, 91, 92
- internal consistency of
64:130
- laryngeal neoplasms
67:35; 71:277-279
- laryngeal neoplasms, by age
67:149
- laryngeal neoplasms, by amount smoked
67:149
- laryngeal neoplasms, by smoking classification
67:149
- laryngeal neoplasms, cigar smokers vs. nonsmokers
67:35
- laryngeal neoplasms, for men by age
67:148-149
- laryngeal neoplasms, for women
67:153
- laryngeal neoplasms, pipe smokers vs. nonsmokers
67:35
- liver cirrhosis
64:342; 67:184
- liver cirrhosis, by age
67:184
- liver cirrhosis, by sex
67:184
- liver cirrhosis, by smoking classification
67:184
- liver cirrhosis, for men
67:184
- liver cirrhosis, for men by amount smoked
67:184
- longevity and
64:99, 100
- lung neoplasms and
64:28, 29, 133, 163, 164, 175-189
- lung neoplasms, by age
67:134-140
- lung neoplasms, by amount smoked
67:135, 137-140
- lung neoplasms, by sex
67:135, 137-140
- lung neoplasms, by smoking characteristics
67:134-136
- lung neoplasms, by smoking classification
67:139-149
- lung neoplasms, cigar smokers
67:140
- lung neoplasms, for men
67:34, 134-135, 137-139
- lung neoplasms, for women
67:34, 153
- lung neoplasms, in Japanese males by amount smoked
72:61
- lung neoplasms, in males by cigarette smoking duration
71:240, 244
- lung neoplasms in smokers in Norway and Finland
71:246
- lung neoplasms, pipe smokers
67:140
- measurement limitations of
64:98
- mouth neoplasms
67:35
- mouth neoplasms, by age and amount smoked
67:146
- mouth neoplasms, by smoking classification
67:146
- mouth neoplasms, cigar smokers vs. nonsmokers
67:35, 146
- mouth neoplasms, for women
67:153
- mouth neoplasms, pipe smokers vs. nonsmokers
67:35, 146
- neoplasms, by site
64:149
- in occasional smokers
64:163
- occupational exposure and
64:112

pancreatic neoplasms, by sex
 67:158
 pancreatic neoplasms, for men by age
 67:159
 pancreatic neoplasms, for men by amount smoked
 67:159
 pancreatic neoplasms, for men by smoking classification
 67:159
 pancreatic neoplasms, for women
 67:153
 from pancreatic neoplasms in smokers and nonsmokers
 71:289-299
 peptic ulcer, for men by age
 67:181
 from peptic ulcer in smokers and nonsmokers
 71:424
 peptic ulcer, smokers vs. ex-smokers by age
 67:181
 pharyngeal neoplasms
 67:35
 pharyngeal neoplasms, by age and amount smoked
 67:146
 pharyngeal neoplasms, by smoking classification
 67:146
 pharyngeal neoplasms, cigar smokers vs. nonsmokers
 67:35
 pharyngeal neoplasms, for women
 67:153
 pharyngeal neoplasms, pipe smokers vs. nonsmokers
 67:35
 pharyngeal neoplasms, smokers vs. nonsmokers
 67:3
 in pipe and cigar smokers by age and inhalation
 73:184, 187
 previous respiratory history and
 64:112
 psychological factors in
 64:101
 sampling in
 64:95, 98, 99
 smokers vs. nonsmokers, from lung neoplasms
 71:240-243
 stability of
 64:117
 stomach neoplasms, by age
 67:157
 stomach neoplasms, by amount smoked
 67:157
 stomach neoplasms, by smoking classification
 67:157
 stroke, by age
 69:12-13
 stroke, by amount smoked
 69:12-13
 stroke, by sex
 69:12-13
 stroke, for men
 67:67
 stroke, for men by amount smoked
 67:67
 stroke, smokers vs. ex-smokers
 69:15
 stroke, , smokers vs. nonsmokers
 69:12-13, 15
 thrombosis, by age
 67:36
 thrombosis, by smoking history
 67:26
 underestimation of
 64:111
 urban-rural differences in
 64:99
 urinary tract neoplasms, by age
 67:154
 urinary tract neoplasms, by smoking classification
 67:154
 urogenital neoplasms, by amount smoked
 67:154
 in white population
 64:132
 Motor vehicle exhaust hydrocarbons as
 64:296
 Mouth
 retention of tar in
 64:264
 Mouth epithelium
 histopathological change in
 64:271
 keratinization of
 64:203
 smoking effect on
 64:275
 Mouth neoplasms
 and cigar smoking by age
 67:146
 and cigar smoking in men
 67:146
 experimental induction by pipe tobacco smoke
 67:147-148
 frequency in smokers and nonsmokers
 71:238
 mortality rates, by age
 67:146
 mortality rates, by amount smoked
 67:146
 mortality rates, by smoking classification
 67:146-147
 mortality rates, for women
 67:153
 mortality rates in United States
 67:145
 mortality ratios
 67:35
 mortality ratios, by smoking classification
 67:35, 146
 mortality ratios, cigar smokers, men, by age
 67:146

- mortality ratios, for men by age
 - 67:146
- mortality ratios, for pipe smokers
 - 67:35, 146
- and smoking
 - 67:35, 145-147
- smoking induced
 - 71:12
- and tobacco use
 - 67:145
- in women, smokers vs. nonsmokers
 - 67:153
- see also* Gingival neoplasms; Lip neoplasms; Oral neoplasms; Palatal neoplasms; Salivary gland neoplasms; Tongue neoplasms
- Mucociliary transport
 - effect of smoking
 - 74:101, 102
- Mucopolysaccharides
 - function as surfactants in lung tissue
 - 71:172
- Mucous cells
 - hyperplasia in
 - 64:272
 - hypertrophy of
 - 64:271
 - increase in number of
 - 64:269
- Mucous glands
 - abnormalities, in smokers vs. nonsmokers
 - 74:97
 - morphological changes in
 - 64:35, 268, 271
- Mucous membranes
 - effect of cigarette smoke on
 - 67:140
 - effect of smoking on
 - 67:144
 - irritation of
 - 64:73
 - smoking and neoplasms of
 - 69:58
- Mucus
 - alterations in
 - 64:268
 - reduction of, by smoke
 - 64:270
 - secretion
 - 64:268, 269, 270
- Muscles, skeletal
 - curariform action of nicotine in
 - 64:69
- Mussels
 - ciliary function in, effects of cigarette smoke on
 - 71:221, 222
- Mustard gas
 - 64:195, 196
- Mutation rate
 - hypothesized variation in
 - 64:192
- Myocardial infarct
 - 64:320, 323
 - acute, and smoking effects on blood circulation in coronary disease patients
 - 67:62
- cholesterol levels and relapse rate
 - 68:23
- coffee drinking, smoking and
 - 74:8; 75:19, 20
- coronary thrombosis and
 - 64:321
- damage to rabbits after exposure to carbon monoxide
 - 75:29
- in Danish twins
 - 71:51
- epidemiological study in Goteborg, Sweden
 - 72:14, 15, 16
- etiology of
 - 69:27-28
- etiology of, smoking as
 - 64:325
- fatal, incidence of, and smoking
 - 67:59
- in German, Japanese, and Norwegian smokers vs. nonsmokers
 - 68:18, 19
- incidence in European vs. American men
 - 73:9
- incidence in male smokers vs. nonsmokers
 - 68:18, 19, 23
- incidence in men in Yugoslavia
 - 73:9
- incidence in men with and without ventricular premature beats
 - 74:10
- incidence in miners in Sardinia
 - 73:10
- incidence in Minnesota men by age and smoking habit
 - 72:14, 15
- incidence in pipe and cigar smokers
 - 73:215
- and incidence of coronary disease
 - 67:53
- incidence rates and smoking
 - 69:21-22; 72:15
- morbidity ratios, for smokers vs. nonsmokers
 - 67:56, 59
- mortality, in smokers vs. nonsmokers
 - 75:14
- nonfatal, morbidity ratios, smokers vs. nonsmokers
 - 67:59
- prevalence in current vs. ex-smokers
 - 74:8
- prevalence in farmers
 - 64:323
- prevalence in smoking vs. nonsmoking men in Czechoslovakia
 - 73:10
- recurrence in smokers vs. nonsmokers, in Buenos Aires
 - 74:9
- and smoking
 - 69:4, 18; 73:19
- and smoking in India
 - 74:8
- summary of previous findings
 - 75:4, 13

- in Swedish women smokers vs. nonsmokers
 - 75:14
 - see also* Coronary diseases
- Myocardium
 - arteriole wall, effects of filtered cigarettes in dogs
 - 72:20
 - arteriole wall thickness in smokers vs. nonsmokers
 - 72:2, 19
 - arteriole wall thickness in smoking and nonsmoking dogs
 - 72:2, 20
 - effect of catecholamines on
 - 67:60
 - effect of cigarette smoking on
 - 67:60; 69:11; 71:5, 8
 - effect of nicotine on
 - 67:60
 - effect of nicotine on catecholamine release from
 - 67:60
 - effect of nicotine on, clinical and experimental studies
 - 67:26
 - effects of hydrogen cyanide in smoke on
 - 71:62
 - oxygen consumption in nicotine stimulated
 - 71:59
 - oxygen demand of, nicotine effects
 - 71:38
 - see also* Heart
- Myosmine
 - structural formula of
 - 64:49
- 2-Naphthylamine
 - development of bladder carcinomas and papillomas in dogs, hamsters, and monkeys
 - 71:296
 - suspected bladder carcinogen in tobacco smoke
 - 71:265
- Naphthols
 - 64:54
- Nas (tobacco and ashes)
 - and oral neoplasms in the USSR
 - 69:58
- Nasopharyngeal neoplasms
 - in smokers vs. nonsmokers, in Taiwan
 - 75:50
- National Cancer Institute
 - 64:7
 - Biometry Branch
 - 64:137, 138, 139
- National Center for Health Statistics
 - 64:13
 - survey of U.S. smoking habits by
 - 71:5-6
 - survey on relationship of smoking and incidence of respiratory disease
 - 71:173
- National Clearinghouse for Smoking and Health
 - responsibilities
 - 71:7
 - survey of smoking, 1970
 - 71:6
- National Cooperative Pooling Project
 - mortality statistics from coronary disease
 - 71:21-22
- National Heart Institute
 - 64:7
- National Institutes of Health
 - 64:13
- National Library of Medicine
 - 64:13, 14
 - assistance in literature review on smoking
 - 71:7
- National Safety Council
 - 64:344
- National Tuberculosis Association
 - 64:8
- National Vital Statistics Division
 - 64:134
- Natural gas
 - respiratory tract carcinoma in workers exposed to
 - 71:256
- Neonates
 - effect of maternal smoking on
 - 67:39, 185-187
 - rats, LD 50, nicotine determination
 - 71:412
 - see also* Birth weight; Infant mortality; Smoking, maternal
- Neoplasms
 - adenomatous, induction in mice by cigarette smoke inhalation
 - 71:350
 - age-adjusted incidence of
 - 64:183
 - benign, in mice
 - 64:165
 - classification of, by World Health Organization
 - 64:173
 - death statistics in, validation of
 - 64:101
 - development in smoking dogs, percentages of
 - 71:274
 - experimental, bronchogenic carcinoma
 - 69:63-64
 - experimental, epidermoid carcinoma
 - 69:64
 - experimental, induction by tobacco smoke
 - 67:35
 - female mortality trends in
 - 64:129, 131, 132, 133, 135, 137
 - induction of
 - 64:33, 143, 146, 147, 148, 166
 - mammalian, cigarette smoke effect on
 - 71:343
 - mortality rates in alcoholics
 - 73:71

- mortality rates in, international statistics of
 - 64:129, 130, 131
- mortality rates in Japan
 - 68:17
- mortality ratios in, by site
 - 64:137, 148, 149
- mortality trends in
 - 64:135, 137
- occupational factors in
 - 64:147
- prevalence of, smokers vs. nonsmokers
 - 69:56
- recurrent primary, incidence in smokers vs. nonsmokers
 - 73:71, 74
- by sex
 - 69:56
- sex ratios in, in mortality
 - 64:132, 133
- by site
 - 64:127, 133, 134, 148, 149, 188, 189, 191, 197, 211
- smoke constituents in, as promoters
 - 64:26, 229
- smoking and
 - 72:4, 5, 59-75
- summary of previous findings on relationship to smoking
 - 68:89, 90; 73:67, 68; 75:3-8
- summary of recent findings on relationship to smoking
 - 73:88; 74:58, 59; 75:43, 54
- by type of tumor and smoking history
 - 69:56
- typing of
 - 64:35
- virus induction of
 - 64:142, 166
- see also Cancer registries; and specific neoplasm terms, e.g., Lung neoplasms
- Nephritis
 - 64:103
- Netherlands
 - cigarette smoke inhalation effects on mice respiratory tract in
 - 71:349
 - lung neoplasms, methods of retrospective study of smoking in
 - 71:323
 - serum lipid difference, in smokers vs. nonsmokers of
 - 71:101
- Neuroticism
 - 64:365, 366, 367
- New Haven Study
 - 64:186
- Newton, Massachusetts study
 - 64:368, 369, 370
- New York City
 - myocardial infarctions in cigar and pipe smokers in
 - 71:32, 38-39
- New York State
 - cancer registry in
 - 64:127, 129
 - neoplasm statistics in
 - 64:135
- New Zealand
 - coronary death rate in
 - 64:320
 - human experimental data on smoking and pregnancy
 - 71:408-409
- Nickel
 - anaplastic changes from
 - 64:166
 - carbonyl, as a cocarcinogen
 - 69:62
 - chloride
 - 64:55
 - cigarette content of, in ash and smoke
 - 64:55, 167
 - compounds, suspected carcinogenic agents in cigarette smoke
 - 71:265; 72:145
 - metaplasia and
 - 64:166
- Nickel workers
 - 64:193, 194, 232
- Nicotine
 - 64:49, 69-75
 - absorption of
 - 64:73, 74, 349
 - acceleration of alpha rhythm by
 - 64:70
 - administration of
 - 64:349
 - antigenic properties
 - 72:104
 - atherogenic effects of
 - 71:120-122
 - carcinogenic effect of
 - 64:144
 - in cigar, pipe, and cigarette smoke
 - 73:177
 - clinical effects on offspring of smoking mothers
 - 73:140, 141
 - coronary heart disease and
 - 74:13, 19
 - degradation of
 - 64:74
 - dosage of
 - 64:74, 352
 - in duodenal ulcer induction in cats
 - 73:158, 159
 - effect as antidiuretic
 - 64:69
 - effect as cerebral anoxia
 - 64:70
 - effect as chronic toxicity
 - 64:32, 73, 74
 - effect as convulsant
 - 64:70
 - effect as curariform action
 - 64:69
 - effect as depressor action
 - 64:74
 - effect as digestive disturbance
 - 64:74
 - effect as discharge pattern
 - 64:70
 - effect as emetic
 - 64:70

effect as nausea
 64:71, 74
 effect as paralysis of ganglia
 64:317
 effect as stimulation
 64:69
 effect as stimulation of ganglia
 64:317
 effect as tranquilization
 64:350
 effect as vasomotor activity
 64:70, 74
 effect during pregnancy
 67:186-187
 effect during pregnancy in laboratory animals
 72:88; 73:115, 116
 effect in "arousal" action
 64:70, 350
 effect on adipose tissue, in rats
 74:13
 effect on apexcardiogram
 72:21
 effect on autonomic nervous system
 67:60
 effect on birth weight in rats
 72:88
 effect on blood circulation
 60:61
 effect on blood circulation in coronary disease patients
 67:61
 effect on blood lipids
 71:123-128
 effect on blood pressure
 64:70; 67:60; 71:36
 effect on blood vessels
 67:62
 effect on bronchoconstrictor response in laboratory animals
 72:46
 effect on cardiac rhythm of heart
 71:36
 effect on cardiovascular system
 67:60; 71:56-58, 107-118
 effect on cardiovascular system in dogs
 73:17
 effect on catecholamine release
 67:60; 71:36, 119; 75:29
 effect on cats
 64:70
 effect on chemoreceptor activity
 64:69
 effect on chemoreflex induction
 64:318
 effect on chlorpromazine inhibition
 64:70
 effect on ciliary activity
 64:268
 effect on colon
 64:71
 effect on dogs
 64:70
 effect on fetus in laboratory animals
 72:88
 effect on gastric secretion
 72:97
 effect on gastric secretion in cats
 73:158, 159
 effect on gastric secretion in rats
 73:159
 effect on gastrointestinal secretion in dogs
 72:6
 effect on habituation
 64:349-354
 effect on heart blood flow in dogs
 73:17
 effect on heart function
 67:60
 effect on heart rate
 67:60; 71:36
 effect on hypercholesterolemic rabbits
 69:27
 effect on immune response in man
 72:109
 effect on lactation in laboratory animals
 73:138, 139
 effect on lactation in smokers vs. non-smokers
 73:139, 140
 effect on lipid biosynthesis in aorta in dogs
 73:17
 effect on lipid metabolism in rabbits
 72:21
 effect on liver
 64:342
 effect on microcirculation in atrium in cats
 73:17
 effect on monkeys
 64:70
 effect on mucus secretion
 64:268, 269
 effect on myocardium
 67:26, 60
 effect on myocardium oxygen demand
 71:38
 effect on myometrial strips in gravidic women
 71:408
 effect on nicotine-sensitive cells
 64:69
 effect on novice smoker
 64:70
 effect on pancreatic secretions in animals
 73:161, 162
 effect on peripheral vascular system
 71:72, 75, 133-134; 72:25, 26
 effect on peritoneal macrophages, in mice
 74:105
 effect on pinocytosis, in mouse peritoneal macrophages
 74:105
 effect on pipe/cigar smoke inhalation
 73:183, 184
 effect on pregnancy
 71:411-414
 effect on pregnant laboratory animals
 67:187-188
 effect on pregnant rats
 69:80

- effect on rabbits
 - 64:70
- effect on rat and mouse fetus, site of action
 - 73:121
- effect on respiration, clinical experimental studies
 - 67:26
- effect on respiratory system
 - 64:70
- effect on respiratory tract in rats
 - 74:104
- effect on supraopticohypophyseal system
 - 64:69
- effect on sympathetic ganglia cells
 - 64:69
- effect on systolic pressure rise
 - 64:74
- effect on vascular resistance in dogs
 - 67:60
- effect, tolerance to
 - 64:353, 354
- effect, toxicity from
 - 64:74
- effect, tremors from
 - 64:70
- effect, unpredictability of
 - 64:69
- excretion, by passive smokers
 - 75:97
- experimental studies
 - 72:21; 73:16, 17
- hypoxia and
 - 72:21
- induction of necrosis in arterial walls
 - 71:63
- as most likely contributor to health hazards of smoking
 - 72:8, 143
- neurogenic effects of
 - 71:57
- N-oxides, presence in tobacco smoke
 - 69:62
- oxidized, in vitro ciliostatic effects
 - 69:42
- as potentiator of duodenal ulcers in animals
 - 73:161-163
- pyrolysis of
 - 64:59
- secretion, effect of cigar, pipe and cigarette smoke in dogs
 - 73:216
- structural formula of
 - 64:49
- substitutes for
 - 64:34, 354
- suppression of immunoglobulin response, in cell cultures
 - 75:77
- systemic toxicity of
 - 64:71, 73
- tissue storage of
 - 64:71
- toleration of
 - 64:352, 353, 354
- toxicity of
 - 64:32, 71, 73, 74, 352, 353, 354
 - see also* Nicotine content; Nicotine metabolism; Nicotine pharmacology
- Nicotine content
 - in blood, new assay methods
 - 73:15, 23
 - and cigarette smoke
 - 72:21
 - and cigarette smoke and tumorigenicity
 - 67:34
 - effects of room size, amount of tobacco burned and ventilation
 - 75:91-94, 97
 - in little cigars compared to cigarettes and cigars
 - 73:223-226, 228
 - in milk of laboratory animals
 - 73:138, 139
 - in milk of smoking mothers
 - 73:139
 - smoker awareness of
 - 64:349
 - and tar content, and tumorigenicity of cigarette smoke
 - 67:15
 - and tar content, of cigarette smoke as measurement of dosage
 - 67:15
- Nicotine metabolism
 - 64:31, 71, 72
 - metabolites
 - 69:61-62
 - metabolites, excretion of
 - 64:71, 72
 - pathways of, in mammals
 - 64:72
 - see also* Cotinine
- Nicotine pharmacology
 - 64:32, 69, 70, 71, 72, 317, 318, 319, 320, 349
 - effect of acetylcholine on
 - 67:60
 - effect of adrenalectomy on
 - 67:60
 - effect of tetraethylammonium chloride on
 - 67:60
- Nine-State Study
 - expected deaths in
 - 64:109
 - mortality ratios in
 - 64:109, 149
 - observed deaths in
 - 64:109
- Nitrates
 - in tobacco smoke
 - 67:128
- Nitric oxide
 - exposure to
 - 64:266
 - as probable contributor to health hazards of smoking
 - 72:144
- Nitrogen
 - gas phase, cigarette smoke
 - 64:60
- Nitrogen bases
 - 64:54

Nitrogen dioxide
 64:60, 266
 ciliastatic effect of
 64:268
 effect on AHH activity
 74:52
 effect on alveolar wall cells in guinea pigs
 73:50
 effect on bacterial retention in hamsters
 73:54
 effect on bactericidal activity in mouse lung
 74:103
 effect on pulmonary physiology, in animals
 74:102-103
 effect on pulmonary physiology, in monkeys
 74:103
 effects on rats' lungs
 69:41; 72:46, 47; 73:49, 50
 in emphysema etiology
 72:46
 obliterative fibrosis from
 64:266
 as probable contributor to health hazards of smoking
 72:144
 pulmonary changes in rodents chronically inhaling
 71:161, 220
 pulmonary edema from
 64:266
 toxic action of
 64:295
 Nitrogen oxides
 64:296, 297
 as air pollutants in cigarette smoke
 74:124, 125
 in cigarette smoke
 64:296, 297
 effects on resistance of squirrel monkeys to pneumococcus
 71:173
 pharmacology of
 64:266
 smoke content of
 64:266
 Nitroglycerine
 effect on blood circulation in coronary disease patients
 67:61-62
 effect on blood circulation in normal individuals
 67:61-62
 4-Nitroquinoline 1-oxide
 alcoholic solution of, development of papillomas in mice drinking
 71:292
 Nitrosamines
 effect on lactating hamsters
 73:139
 role in respiratory tract carcinogenesis, in animals
 74:47
 N-nitrosamines
 69:62
 carcinogenicity
 67:127
 carcinogenicity in cigarette smoke
 71:264-266
 determination in cigarette and tobacco smoke condensate
 73:87, 88
 esophageal neoplasms induced in animals by
 71:292
 in tobacco smoke
 67:127
 N-nitrosoanabasine
 69:62
 N-Nitrosoheptamethyleneimine
 incidence of lung neoplasms, in rats
 75:49
 N-nitrosornicotine
 in tobacco
 69:62; 75:48, 49
 Nonrespondents
 age adjusted death rates in
 64:114
 magnitude of, in surveys
 64:97
 mortality ratios in
 64:116
 proportion of smokers in
 64:114
 Nonresponse bias
 64:96, 104, 115
 Nonsmokers
 age-adjusted mortality in
 64:100
 by age and sex, U.S.
 64:178
 airway resistance in
 64:292, 293
 allergic and irritative reactions to cigarette smoke
 72:128, 129
 allergic skin reactions in
 64:319
 allergic symptoms in, from tobacco smoke exposure
 72:110, 111
 bladder neoplasm risk in
 64:222
 bladder neoplasms in
 64:223
 body weight of
 64:384, 385
 carboxyhemoglobin effects on oxygen uptake
 71:61
 carboxyhemoglobin levels in
 72:125
 chronic cough prevalence in
 64:299, 302
 coronary diseases rate in
 64:322, 323
 emphysema in
 64:297
 epithelial changes in
 64:170, 173, 189
 epithelial changes in, females
 64:170

- extroversion in
 - 64:366
- forced expiratory volume in
 - 64:290, 291
- hemoglobin concentration in
 - 64:319
- I.Q. measurement of
 - 64:370
- liver cirrhosis in
 - 64:342
- lung neoplasms in
 - 64:118, 184, 191, 193, 230, 232
- morphology of
 - 64:385, 386
- mortality rates in
 - 64:100, 102, 117, 118
- mortality ratios in
 - 64:163, 202, 301
- occupational factors in
 - 64:187
- oral neoplasms
 - 64:202
- passive smoking and
 - 72:121-125
- as percent of population
 - 64:114
- pneumoconiosis in
 - 64:298
- psychosomatic disorders in
 - 64:367
- respiratory conditions in
 - 64:289
- risk ratios in
 - 64:222, 223, 230, 232
- urban-rural mortality in
 - 64:186, 194
- U.S., by age
 - 64:178
- see also* Smokers vs. nonsmokers
- Norepinephrine
 - 64:318
- effects of nicotine
 - 75:29
- Nornicotine
 - 69:62
- structural formula
 - 64:49
- North Dakota studies
 - 64:323
- Norway
 - coronary death rates in
 - 64:320
 - incidence rates of lung neoplasms
 - 69:55-56
 - lung neoplasms in, for pipe smokers
 - 71:244
 - lung neoplasms mortality in, relationship to tobacco use
 - 64:176; 71:245-246
 - neoplasm risk in
 - 64:127
 - tracheobronchial tree changes in smokers and nonsmokers of
 - 71:259
- Nose
 - effect of smoking
 - 64:275
- Nose neoplasms
 - 64:193
- mortality rates, by amount smoked
 - 67:147
- mortality rates, by smoking classification
 - 67:147
- Noxious gases
 - exposure magnitude of
 - 64:296, 297
 - in respiratory diseases
 - 64:279
- Nutritional deficiency
 - 64:341
- Oat cell carcinoma
 - see* Carcinoma, oat cell
- Obesity
 - 64:38, 321, 355
 - coronary diseases mortality and
 - 64:321; 71:43
 - relationship to smoking and CHD
 - 71:43-45
 - relationship to smoking in peripheral arteriosclerosis
 - 71:72
 - as risk factor for CHD
 - 72:16; 73:9
- Occupational diseases
 - asbestosis
 - 73:41
 - asbestosis, in asbestos workers, in Singapore
 - 74:95
 - bronchitis
 - 72:42
 - bronchitis and respiratory tract irritation, in rubber industry workers
 - 74:96
 - bronchitis, in cement and rubber industry workers
 - 74:95, 96
 - bronchitis, in wool and cotton textile workers
 - 74:93, 94
 - byssinosis
 - 73:39, 41
 - byssinosis, in cotton and wool textile workers
 - 74:93, 94
 - byssinosis in cotton millworkers
 - 75:68
 - chronic obstructive pulmonary disease
 - 72:3, 42-44
 - chronic obstructive pulmonary disease, in autoworkers
 - 74:80
 - chronic obstructive pulmonary disease, in firemen
 - 75:68
 - coal workers' pneumoconiosis
 - 73:42
 - lung neoplasms in uranium miners
 - 75:47
 - pneumoconiosis
 - 72:42-44
 - pulmonary fibrosis
 - 72:44

- and risk of neoplasms
 - 75:43
- smoking and
 - 72:3, 42-44; 74:93-96; 75:68-70
- see also Occupational factors; Occupational hazards; Occupations
- Occupational factors
 - 64:224
 - chronic bronchitis and
 - 64:298, 299, 300, 302
 - coronary disease and
 - 64:321, 322; 73:5, 7
 - lung neoplasms and
 - 64:95, 187, 193, 194, 232
 - mortality and
 - 64:112, 134
 - smoking prevalence and
 - 64:362, 363
 - see also Occupational diseases; Occupational hazards; Occupations
- Occupational hazards
 - 64:100, 101, 232
 - air pollution exposure in Boston policemen
 - 74:82, 83
 - asbestos exposure
 - 67:35; 73:41
 - asbestos exposure and smoking as factors in lung neoplasm development
 - 74:41-43; 75:49
 - in bladder neoplasms
 - 64:222
 - bladder neoplasms, and smoking
 - 73:78
 - carboxyhemoglobin levels in workers exposed to exhaust gases
 - 75:21
 - coal dust exposure
 - 73:41-43
 - from coal tar
 - 64:147
 - cotton, flax, and hemp dust exposure
 - 73:39-41
 - dust exposure
 - 73:43, 44
 - exposure to chemicals, fumes, sprays and dusts, in smokers vs. nonsmokers, by race and sex
 - 75:69, 70
 - exposure to 100% pure oxygen
 - 73:43
 - higher reporting of exposure to, by smokers vs. nonsmokers
 - 75:68
 - in lung neoplasms
 - 64:232
 - myocardial infarction as
 - 64:323
 - nitrogen dioxide in
 - 64:266
 - pancreatic neoplasms and
 - 73:77
 - pulmonary disease from
 - 64:266, 298, 299, 300, 302
 - radiation exposure in uranium miners
 - 73:72
 - risk ratios in
 - 64:31, 134
 - rubber industry fumes and smoking
 - 74:96
 - smoking and
 - 72:3, 4, 42-44; 73:39-44
 - smoking as additive risk for COPD
 - 73:55
 - textile dust exposure and smoking
 - 74:93-96
 - uranium exposure
 - 67:35
 - see also Occupational diseases; Occupational factors; Occupations
- Occupations
 - asbestos workers, lung neoplasm morbidity
 - 67:143
 - asbestos workers, lung neoplasm mortality and smoking
 - 71:257
 - asbestos workers, respiratory tract carcinoma
 - 71:256
 - bank employees, smoking and COPD
 - 71:198
 - coal miners, impaired pulmonary function in smoking
 - 71:163
 - coal miners, respiratory tract carcinoma
 - 71:256
 - coal miners, smoking and COPD
 - 71:153, 197, 218-219
 - coal miners, smoking and ventilatory function
 - 71:207
 - flax mill workers, smoking and COPD
 - 71:199
 - government employees, blood pressure differences in smokers vs. nonsmokers
 - 71:99
 - longshoremen, mortality from smoking-related cerebrovascular disease
 - 71:70
 - longshoremen, mortality rates from CHD in
 - 71:28
 - longshoremen, smoking and COPD
 - 71:28
 - longshoremen, smoking and ventilatory function
 - 71:208
 - medical students, serum lipid differences in smokers vs. nonsmokers
 - 71:98
 - medical students, smoking and nicotine effects on blood lipid levels
 - 71:124
 - medical students, smoking and thrombosis relationships
 - 71:130
 - medical students, smoking and ventilatory function
 - 71:209-210
 - mortality rates, smokers vs. nonsmokers by
 - 67:11
 - nickel workers, lung neoplasms in
 - 71:256

- physicians, bladder and kidney neoplasms in smoking
71:293, 294
- physicians, cessation of smoking effect on COPD
71:142
- physicians, COPD mortality rates
71:149
- physicians, decline in cigarette smoking rates
71:48
- physicians, mortality from smoking-related cerebrovascular disease
71:68
- physicians, mortality rates from CHD
71:26
- physicians, mortality ratios from esophageal neoplasms
71:290
- physicians, mortality ratios from peptic ulcer in smoking and nonsmoking
71:424
- physicians, pulmonary function following cessation of smoking
71:149
- physicians, smoking and ventilatory function
71:209-210, 213
- plant workers, occupational exposure and smoking relationships to COPD
71:153, 218, 219
- plant workers, smoking and COPD
71:198
- plant workers, smoking and ventilatory function
71:206-208
- post office workers, blood pressure differences in smokers vs. nonsmokers
71:104
- post office workers, smokers and ventilatory function
71:209
- post office workers, smoking and COPD
71:200, 202
- prisoners, serum lipid differences in smokers vs. nonsmokers
71:100
- prisoners, smoking and nicotine effects on peripheral vascular system
71:133
- railroad employees, mortality and morbidity, CHD and smoking
71:28, 34, 97
- and respiratory symptoms by smoking habit
67:97
- smelter workers, lung neoplasm mortality from arsenic exposure
71:257
- smoking habit for
67:143
- soldiers, smoking and COPD
71:197
- steel workers, COPD development from dust exposure
71:153
- students, carbon monoxide effects on blood lipids
71:129
- students, infectious respiratory disease in smokers vs. nonsmokers
71:228-229
- students, mortality from smoking-related cerebrovascular disease
71:68
- students, mortality rates from CHD
71:28
- students, smoking and COPD
71:201
- students, smoking and nicotine effects on blood lipid level
71:125
- students, smoking and thrombosis relationships
71:130
- students, smoking and ventilatory function
71:211
- telephone company employees, smoking and COPD
71:200
- textile workers, occupational exposure and smoking relationship to COPD
71:218-219
- transportation workers, air pollution relationship to COPD
71:198, 202
- transportation workers, smoking and COPD
71:198, 202
- transportation workers, smoking and ventilatory function
71:207, 212
- uranium miners, lung neoplasms in smokers and nonsmokers
71:256
- uranium miners, lung neoplasms morbidity by smoking habit for
67:143
- utility company employees, CHD morbidity in smoking
71:30
- veterans, bladder and kidney neoplasms in smoking
71:294-295
- see also* Occupational diseases; Occupational factors; Occupational hazards
- Office of Science and Technology
64:8
- Oleic acid
suspected carcinogenic agent in cigarette smoke
71:266
- Olive oil
penetrability of benzo(a)pyrene in mice esophageal epithelium
71:292
- Opium
64:349
- Optic nerve
atrophy, and cyanide in tobacco smoke
67:183
- sensitivity, amblyopia from
64:341
- Oral diseases, non-neoplastic smoking and
69:5-6, 85-87; 72:6

- Oral hygiene
 - relationship to smoking and noncancerous oral disease
 - 69:85-86
 - smoking and
 - 72:6
- Oral mucosa
 - 64:203
 - effect of carcinogens in laboratory animals
 - 72:70
 - effect of cigarette smoke
 - 72:6, 69
 - effect of reverse smoking
 - 72:69
 - effect of tobacco/bidi smoking and chewing
 - 72:69
- Oral neoplasms
 - 64:37, 196-204, 233
 - alcohol consumption and smoking in etiology of
 - 73:193; 74:53-55
 - amount smoked in
 - 64:233
 - cigar smoking in
 - 64:189
 - epidemiologic studies
 - 64:196-202; 74:53-55
 - estimated incidence in U.S. for 1970
 - 71:284
 - experimental induction of
 - 64:233
 - incidence of secondary primary, in smokers vs. nonsmokers
 - 75:50
 - income gradients in
 - 64:134
 - inhalation patterns and
 - 73:191
 - mortality rates in
 - 64:37, 133; 71:285
 - mortality rates in, in females
 - 64:131, 132
 - mortality rates in, in foreign born
 - 64:134
 - mortality rates in, in Irish
 - 64:135
 - mortality rates in, in males,
 - 64:130, 132
 - mortality rates in Japanese male smokers vs. nonsmokers
 - 73:74
 - mortality ratios for pipe, cigar, and cigarette smokers vs. nonsmokers
 - 73:191-193
 - mortality ratios in
 - 64:113, 202
 - mortality ratios in, in cigarette smokers
 - 64:149
 - mortality trends in
 - 64:137
 - neoplasm site by tobacco use in
 - 64:197
 - pipe smoking in
 - 64:37, 150, 189; 72:67
 - prevalence of, decline in
 - 64:204
 - recurrent, incidence in smokers vs. ex-smokers
 - 73:71, 74-75
 - relationship of tobacco use
 - 71:285, 289, 361-367
 - relative risk in tobacco smokers and chewers
 - 72:70
 - relative risk of development in pipe, cigar, and cigarette smokers vs. non-smokers
 - 73:191, 194, 195
 - retrospective studies of
 - 64:198, 199, 200, 201
 - reverse smoking in
 - 64:203, 204; 73:76
 - risk gradients in, by amount smoked
 - 64:233
 - risk ratios in, in females
 - 64:134
 - smoking induced increase in
 - 64:197
 - smoking in etiology of
 - 64:204; 69:58; 71:289; 72:4, 67-70; 73:74-76
 - snuff in
 - 64:233
 - summary of previous findings on relationship to smoking
 - 74:52, 53
 - summary of retrospective studies
 - 73:194, 195
 - and tobacco chewing
 - 69:58
 - urban-rural factors in
 - 64:133
 - in waiters
 - 64:134
 - see also* Gingival neoplasms; Mouth neoplasms; Oropharyngeal neoplasms
 - Oral ulceration
 - reverse smoking in
 - 64:203
 - Organ cultures
 - cigarette smoke effects on cell growth and reproduction in
 - 71:267, 343-345
 - Oropharyngeal neoplasms
 - 64:201
 - frequency in smokers and nonsmokers
 - 71:238
 - Oxidoreductases
 - reduction of, in smokers' alveolar macrophages
 - 69:42-43
 - Oxygen
 - in cardiac function
 - 64:318
 - debt, effect of smoking
 - 73:246, 247
 - debt, exercise performance and
 - 73:246, 247
 - myocardial consumption of, following nicotine stimulation
 - 71:58, 75
 - in smoke
 - 64:60

- tension, smokers vs. nonsmokers
72:22
- transport in body, carbon monoxide effects
71:60, 75
- uptake in nonsmokers with specific carboxyhemoglobin levels
71:61, 75
- Ozone
 - ciliastasis from
64:268
 - irritation action of
64:295
- Ozonized gasoline
64:166

- Pachyderma oralis
64:203
- Palatal mucosa
64:275
- Palatal neoplasms
64:204
see also Mouth neoplasms; Oral neoplasms
- Palate
 - hamster, C-14 labeled smoke particulates deposition in
71:281-282
 - smoking and stomatitis nicotina
69:87
- Pancreatic neoplasms
 - incidence in cigar/pipe and cigarette smokers vs. nonsmokers
74:55, 56
 - mortality rates, by age
67:158-159
 - mortality rates, by amount smoked
67:159
 - mortality rates, by sex
67:158
 - mortality rates, by smoking classification
67:159
 - mortality rates, for women
67:153
 - mortality rates in United States
72:74
 - mortality ratios, by age
67:158-159
 - mortality ratios, by age and amount smoked
67:159
 - mortality ratios, by sex
67:158
 - mortality ratios, for men by smoking classification
67:159
 - mortality ratios, for women
67:153
 - mortality ratios in Japanese male and female smokers
72:74
 - occupational exposure and
73:77
 - relationship of smoking to mortality from
71:298-299
- relative risk in men by number of cigarettes smoked
74:55
- smoking and,
67:36, 158-159; 69:60-61; 71:13, 238, 298-299; 72:5, 68, 74; 73:77
- summary of previous findings on relationship to smoking
74:55
- Pancreatic secretions
 - bicarbonate content, effect of smoking
73:159, 160
 - effect of nicotine in animals
73:161, 162
- Papain
 - pulmonary effects on rats exposed to cigarette smoke with
71:163
- Paper chromatography
64:51, 57
- Papillomas
 - 64:142, 165
 - development in mice drinking alcoholic benzopyrene
71:292
 - formation following skin painting with smoke tars
71:337-339, 341
 - induction in hamsters exposed to benzo(a)pyrene
71:346-347
 - induction of
64:142, 143, 144, 203, 223
 - transformation of
64:144
- Papillomas, benign
 - 64:142
 - origin of,
64:165
 - tar induced, in mice
64:223
- Paraffin
64:147
- Paralysis
 - of ganglionic nerve cells
64:69
- Paralysis agitans
 - mortality rates, smokers vs. nonsmokers
67:8
- Parasorbic acid lactone
64:145
- Parathion
62:145
- Parents
 - incidence of pneumonia and bronchitis in children of smokers
75:105, 106
 - influence
64:369, 370
 - prevalence of respiratory symptoms in children of smokers
75:102, 103
 - smokers cough and phlegm production, and respiratory symptoms in children
75:103
 - see also* Smoking, parental
- Paris green
64:61